Philadelphia Chromosome Positive Chronic Myelogenous Leukemia Clinical Trial
Official title:
A Single-arm Dose-finding Phase Ib Multicenter Study of the Oral Smoothened Antagonist LDE225 in Combination With Nilotinib in Chronic or Accelerated Phase of Chronic Myeloid Leukemia Patients Who Have Failed Prior Therapy With Other BCR-ABL Tyrosine-kinase Inhibitors
| Verified date | September 2016 |
| Source | Novartis |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to determine the feasibility of administering the combination of nilotinib and LDE225 to patients with chronic or accelerated phase of chronic myeloid leukemia and to establish the maximum tolerated dose (MTD) and/or recommended Phase II dose level (RP2D) of LDE225 in combination with nilotinib.
| Status | Completed |
| Enrollment | 11 |
| Est. completion date | February 2014 |
| Est. primary completion date | February 2014 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: 1. Philadelphia chromosome positive (Ph+) CML in chronic phase (CP) or accelerated phase (AP)with resistance to at least one prior BCR-ABL targeting TKI 2. Documented chronic phase CML 3. Adequate end organ function 4. Female patients of childbearing potential must have a negative serum pregnancy test and must be using highly effective methods of contraception. Male patients with female partners of child-bearing potential must use condoms. Exclusion Criteria: 1. Impaired cardiac function 2. Severe and/or uncontrolled concurrent disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol 3. History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis 4. Patients actively receiving therapy with strong CYP3A4 inhibitors and/or inducers, and the treatment cannot be either discontinued or switched to a different medication prior to entering the study 5. Patients who are currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either safely discontinued or switched to a different medication prior to starting study drug. 6. Previously documented BCR-ABL Y253H, E255K/V, T315I or F359C/V mutation Other protocol-defined inclusion/exclusion criteria may apply. |
| Country | Name | City | State |
|---|---|---|---|
| Canada | Novartis Investigative Site | Toronto | Ontario |
| France | Novartis Investigative Site | Marseille | |
| Germany | Novartis Investigative Site | Frankfurt | |
| Germany | Novartis Investigative Site | Ulm | |
| Italy | Novartis Investigative Site | Roma | RM |
| Spain | Novartis Investigative Site | Madrid | |
| Spain | Novartis Investigative Site | Pamplona | Navarra |
| Lead Sponsor | Collaborator |
|---|---|
| Novartis Pharmaceuticals |
Canada, France, Germany, Italy, Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Incidence rate and category of dose limiting toxicities (DLTs) during the first two cycles of therapy | Determination of the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of nilotinib in combination with LDE225 | 56 days (2 treatment cycles at 28 days each) | |
| Secondary | No of participants with Adverse drug reactions and serious adverse drug reactions, changes in hematology and blood chemistry values, assessments of physical examinations, vital signs and electrocardiograms | Assessment of the safety and tolerability profile of nilotinib in combination with LDE225 | 336 days (12 treatment cycles) | |
| Secondary | Plasma concentration and basic pharmacokinetics (PK) parameters (as Cmax, Tmax, AUC) | Assessment of the PK characteristics of nilotinib administered in combination with LDE225 | 50 days | |
| Secondary | Major molecular response (MMR) rates at 3, 6 and 12 months | Determination of the kinetics of major molecular response | 336 days (12 treatment cycles) | |
| Secondary | Complete molecular response (CMR) rates at 3, 6 and 12 months | Determination of the kinetics of complete molecular response | 336 days (12 treatment cycles) | |
| Secondary | Major cytogenic response (MCyR) rates by 3, 6 and 12 months | Determination of major cytogenetic response rates | 336 days (12 treatment cycles) | |
| Secondary | Complete cytogenic response (CCyR) rates by 3, 6 and 12 months | Determination of complete cytogenetic response rates | 336 days (12 treatment cycles) |